GEN Exclusives

More »

GEN News Highlights

More »
Aug 8, 2007

Xenomics’ Diagnostic Test for AML Available to Clinicians

  • Xenomics reports that its first diagnostic test for stratification of patients with acute myeloid leukemia (AML) has been implemented at CLIA approved BRT Laboratories and is available to clinicians.

    This test is based on a recent discovery that mutations in a nucleophosmin (NPM1) gene are characteristic of 30% to 40% of the cases of AML. NPM1 is a protein involved in regulation of ribosome biogenesis, cell division, cell death, and other important processes, Xenomics states. The company says that it has developed a diagnostic tool that detects all 45 known mutations of NPM1 in a single reaction.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Genetics and Intelligence

Do you believe research on the genetics of intelligence can improve education?

More »